These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31074667)

  • 1. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
    Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
    Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
    Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C; Chazouillères O; Poupon R
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease.
    Cortez-Pinto H; Liberal R; Lopes S; Machado MV; Carvalho J; Dias T; Santos A; Agostinho C; Figueiredo P; Loureiro R; Martins A; Alexandrino G; Cotrim I; Leal C; Presa J; Mesquita M; Nunes J; Gouveia C; Vale AHE; Alves AL; Coelho M; Maia L; Pedroto I; Banhudo A; Pinto JS; Gomes MV; Oliveira J; Andreozzi V; Calinas F
    United European Gastroenterol J; 2021 Jul; 9(6):699-706. PubMed ID: 34102008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.
    Guo GY; Shi YQ; Wang L; Ren X; Han ZY; Guo CC; Cui LN; Wang JB; Zhu J; Wang N; Zhang J; Cai Y; Han Y; Zhou XM; Fan DM
    Aliment Pharmacol Ther; 2015 Jul; 42(2):221-30. PubMed ID: 25982180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
    Lammers WJ; Leeman M; Ponsioen CI; Boonstra K; van Erpecum KJ; Wolfhagen FH; Kuyvenhoven JP; Vrolijk JM; Drenth JP; Witteman EM; van Nieuwkerk CM; van der Spek BW; Witteman BJ; Erkelens GW; Verhagen MA; van Tuyl SA; Poen AC; Brouwer JT; Ter Borg F; Koek GH; van Ditzhuijsen TJ; Hansen BE;
    Neth J Med; 2016 Jul; 74(6):240-6. PubMed ID: 27571721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
    Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
    Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
    [No Abstract]   [Full Text] [Related]  

  • 13. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
    Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
    EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia.
    AlWabel AH; Peedikayil M; AlNasser S; AlHusaini K; AlHekail O; Alqahtani SA; AlTraif IH; AlAshgar H
    Saudi J Gastroenterol; 2023; 29(2):135-140. PubMed ID: 35229756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
    Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
    Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis.
    Cançado GGL; Fucuta PDS; Gomes NMF; Couto CA; Cançado ELR; Terrabuio DRB; Villela-Nogueira CA; Braga MH; Nardelli MJ; Faria LC; Oliveira EMG; Rotman V; Oliveira MB; Cunha SMCFD; Silva MCD; Mendes LSC; Ivantes CAP; Codes L; de Almeida E Borges VF; Pace FHL; Pessôa MG; Signorelli IV; Coral GP; Bittencourt PL; Ferraz MLG
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102453. PubMed ID: 39174006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.